Filtered By:
Condition: Ischemic Stroke
Drug: Prednisone
Education: Study

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 8 results found since Jan 2013.

Progression of Large Vessel Disease in Patients With Giant Cell Arteritis–Associated Ischemic Stroke: The Role of Vascular Imaging: A Case Series
Conclusions Vascular imaging, especially with color-coded duplex sonography, could play a role in the follow-up of patients with GCA-related IS and identify those patients with higher risk of recurrent stroke.
Source: JCR: Journal of Clinical Rheumatology - December 1, 2021 Category: Rheumatology Tags: Original Articles Source Type: research

Fluctuating Mental Status and Fever of Unknown Origin (P1.030)
Conclusion: Central nervous system involvement as the initial manifestation of microscopic polyangiitis is rare and can result in a challenging clinical picture including recurrent ischemic strokes.Disclosure: Dr. Daniel has nothing to disclose. Dr. Brink has nothing to disclose. Dr. Hosley has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Daniel, A., Brink, J., Hosley, C. Tags: Cerebrovascular Disease and Interventional Neurology: Case Reports Source Type: research

Primary Angiitis of the Central Nervous System (PACNS) Presenting with Intracerebral Hemorrhage (P2.293)
Conclusion: Primary CNS vasculitis should be suspected even in patients presenting initially with intracerebral hemorrhage in association with only moderate headaches.Disclosure: Dr. Alkhalifah has nothing to disclose. Dr. Fayad has received research support from the National Institute of Neurological Disorders and Stroke and St. Jude Medical. Dr. Omojola has nothing to disclose. Dr. Hearth-Holmes has nothing to disclose. Dr. McComb has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Alkhalifah, M., Fayad, P., Omojola, M., Hearth-Holmes, M., McComb, R. Tags: Cerebrovascular Disease and Interventional Neurology: Inflammation and Immunology Source Type: research

Deadly Respiratory Distress Mimic
Conclusion It’s important for prehospital providers to be able to differentiate metabolic disturbances in the setting of respiratory distress and not be fooled into thinking tachypnea always has a respiratory cause. The physical exam and adjuncts such as end-tidal capnography can assist in the prehospital diagnosis. A COPD exacerbation generally presents as diminished lung sounds, wheezing on exhalation, and a prolonged expiratory phase. Here, a patient will attempt to compensate for the inflammation and mucus accumulation associated with the destruction and narrowing of peripheral airways and a subsequent lack of availa...
Source: JEMS Special Topics - July 17, 2018 Category: Emergency Medicine Authors: Brenton Faber, PhD, NRP Tags: Airway & Respiratory Exclusive Articles Patient Care Source Type: news

Neuro-Beh çet in a Sub-Saharan Africa Country: a Series of Sixteen Patients in Fann Teaching Hospital, Dakar, Senegal.
[Neuro-Behçet in a Sub-Saharan Africa Country: a Series of Sixteen Patients in Fann Teaching Hospital, Dakar, Senegal]. Bull Soc Pathol Exot. 2019;112(3):137-146 Authors: Gaye NM, Ndiaye-Diop MT, Fall M, Ka M, Fall SAA, Diop AM, Kahwaji J, Cissé-Diallo VMP, Mbaye M, Thioub M, Mbodji AB, Mbaye KA, Diagne R, Bakhoum M, Cissé O, Bâ EHM, Diagne NS, Diop-Sène MS, Basse-Faye AM, Sow AD, Sarr MM, Seck LB, Touré K, Ndiaye M, Diop AG Abstract Neuro-Behçet (NB) African studies are mainly North African, but Sub-Saharan Africa is not to be outdone. Our aim was to describe diagnostic and therapeutic features...
Source: Bulletin de la Societe de Pathologie Exotique - December 13, 2019 Category: Tropical Medicine Tags: Bull Soc Pathol Exot Source Type: research

Janssen Demonstrates Commitment to Advancing Science and Innovation in the Treatment of Solid Tumors at ESMO Annual Congress
September 8, 2021 (RARITAN, N.J.) – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that more than ten data presentations from its lung cancer, bladder cancer and prostate cancer portfolio and pipeline will be featured during the European Society for Medical Oncology (ESMO) Annual Congress 2021 virtual meeting, September 16–21. Further details about these data and the science Janssen is advancing will be made available throughout ESMO via the Janssen Oncology Virtual Newsroom.“With a diverse oncology portfolio and pipeline spanning bladder cancer, lung cancer and prostate cancer, Janssen...
Source: Johnson and Johnson - September 8, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Data at ASCO GU Demonstrate Longstanding Leadership in Prostate Cancer and Commitment to Advancing Potential New Therapeutic Options for Genitourinary Cancers
Raritan, NJ, Feb. 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today that 17 presentations will be featured at the 2022 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, taking place in San Francisco and virtually from February 17-19. Building on its long-term leadership in prostate cancer, Janssen is committed to advancing innovative treatments and transforming patient experiences, while focusing on research that may drive better outcomes for people across the genitourinary cancer spectrum. Data to be presented include Phase 3 results for the selective ...
Source: Johnson and Johnson - February 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news

Janssen Data at ASCO GU Support Ambition to Transform Treatment of Prostate and Bladder Cancer Through Precision Medicine and Early Intervention
RARITAN, N.J., February 13, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced plans to present more than 20 abstracts featuring seven oncology therapies from its robust portfolio and pipeline at the annual American Society of Clinical Oncology (ASCO) Genitourinary (GU) Cancers Symposium, taking place in San Francisco on February 16-18. Building on more than a decade of leadership in the development of medicines for people diagnosed with GU cancers, Janssen will present data demonstrating its ambition to advance patient-centered treatment through precision medicine, real-world evidence a...
Source: Johnson and Johnson - February 13, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news